FIELD: medicine, hepatology. SUBSTANCE: method involves administration of moxonidine by oral route in the dose 0.2-0.4 mg per 24 h for 2-4 months. Invention promotes to the enhancement of therapy effectiveness by improvement of clinical-laboratory data. Invention can be used for treatment of hepatic diseases. EFFECT: enhanced effectiveness of treatment. 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR TREATING HEPATIC DISEASES | 2000 |
|
RU2180227C1 |
METHOD FOR TREATMENT OF LIVER DISEASE | 2004 |
|
RU2286773C2 |
METHOD FOR APPLYING PHYSIOTHERAPEUTIC LIVER TREATMENT | 2002 |
|
RU2232609C2 |
METHOD FOR EVALUATING HEPATIC HEMODYNAMICS | 2002 |
|
RU2214158C1 |
METHOD OF TREATMENT OF LIVER DISEASES | 2006 |
|
RU2334499C2 |
METHOD FOR TREATING CHRONIC LIVER DISEASES AGGRAVATED BY HBsAg CARRIAGE WITH LOW INTENSITY HELIUM-NEON LASER IRRADIATION OF BLOOD | 1995 |
|
RU2144836C1 |
METHOD FOR CARRYING OUT RHEOHEPATOGRAPHIC EXAMINATION | 2001 |
|
RU2218070C2 |
METHOD FOR PREDICTING COMPLICATIONS OCCURRENCE RISK CAUSED BY PLASMAPHERESIS ACTION UPON CHRONIC HEPATIC DISEASE PATIENTS | 2006 |
|
RU2321337C1 |
METHOD FOR TREATING THE PATIENTS SUFFERING FROM HEMOCHROMATOSIS BY APPLYING CYTOPHERESIS | 1996 |
|
RU2146543C1 |
METHOD FOR TREATING THE CASES OF CHRONIC LIVER DISEASES WITH HEPATIC INSUFFICIENCY MANIFESTATIONS BY MEANS OF PLASMAPHERESIS | 1995 |
|
RU2146948C1 |
Authors
Dates
2003-12-27—Published
2001-09-24—Filed